内分泌学会原发性醛固酮增多症管理指南的系统综述
本系统综述纳入95项研究(7项随机试验和88项观察性研究),评估原发性醛固酮增多症(PA)筛查、诊断和治疗的相关结局,为内分泌学会PA管理临床实践指南的制定提供依据。综述涉及筛查效果、肾上腺静脉采血与CT比较、手术与药物治疗比较及螺内酯与依普利酮比较等,并指出多数证据确定性较低。
要点
- 筛查可能与提高PA特异性药物使用率和改善血压控制相关,但缺乏随机试验证据。
- 肾上腺静脉采血(对比单独CT)可能提高术后生化治愈率,但增加肾上腺出血风险。
- 手术可能比药物更好地控制血压并减少降压药数量与剂量;螺内酯可能优于依普利酮。
核心结论
- 本系统综述涵盖PA管理的多个方面,将为内分泌学会指南制定提供支持。
- 现有证据多为观察性研究且确定性较低,需谨慎解读。
研究设计与样本
- 纳入95项研究,包括7项随机试验和88项观察性研究。
主要发现
- 未发现评估PA筛查结局的随机试验;一项观察性研究提示筛查与更高PA特异性药物使用率和更好血压控制相关。
- 肾上腺静脉采血(对比单独CT)可能提高术后生化治愈率,但增加肾上腺出血风险。
- 两项小型观察性研究提示PA特异性药物或手术治疗可能比非特异性治疗血压控制更好。
- 小型随机试验提示手术治疗可能比药物治疗血压控制更好,且降压药数量与剂量更少。
- 与依普利酮相比,螺内酯可能更好控制低钾血症并减少降压药数量与剂量。
临床怎么用
- 临床决策应结合现有低确定性证据,个体化选择筛查、诊断和治疗策略。
- 肾上腺静脉采血可提高术后生化治愈率,但需权衡肾上腺出血风险。
- 手术和药物治疗均可考虑,手术可能血压控制更优且减少降压药需求。
- 螺内酯可能比依普利酮更利于低钾血症和血压控制。
- 血浆肾素活性抑制者可能死亡、房颤和卒中风险更高,需加强评估。
局限性
- 多数证据来自观察性研究或小型随机试验,总体确定性较低。
- 未发现评估PA筛查结局的随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Primary aldosteronism (PA) is a leading endocrine cause of secondary hypertension. OBJECTIVE: To support the development of the Endocrine Society Clinical Practice Guideline on managing PA. DATA SOURCE: MEDLINE, Embase, Scopus, and others were searched on October 4, 2024. STUDY SELECTION: Studies were selected by pairs of independent reviewers. DATA EXTRACTION: Data were extracted and appraised by pairs of independent reviewers. DATA SYNTHESIS: We included 95 studies (7 randomized trials and 88 observational studies). We did not identify trials that evaluated the outcomes of PA screening. One observational study suggested that screening was associated with higher rates of using PA-specific medical therapies and better blood pressure control. Patients managed with adrenal venous sampling (vs computed tomography alone) may have a better post-adrenalectomy biochemical cure rate, but with an increased risk of adrenal hemorrhage. Two small observational studies suggested that PA-specific medical or surgical therapy was likely associated with better blood pressure control than nonspecific therapy. Small randomized trials suggested that surgical therapy may be associated with better blood pressure control than medical therapy, with a lower number and dosage of antihypertensive medications. Compared to eplerenone, spironolactone may be associated with better control of hypokalemia and a lower number and dosage of antihypertensive agents. Unsuppressed plasma renin activity was associated with better control of hypokalemia, while suppression was associated with higher risk of mortality, atrial fibrillation, and stroke (very low certainty). CONCLUSION: This systematic review addresses various aspects of managing PA and will support the development of the Endocrine Society guidelines.
引用
- Farah MH, Hegazi M, Firwana M, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on Management of Primary Aldosteronism. J Clin Endocrinol Metab. 2025. PMID: 40658500. doi:10.1210/clinem/dgaf290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。